The Store That Sells the Right

Companion, on the other side of the counter, to Behind Every Test, an Industry. That piece described how the medical mainstream chooses the nutrients it measures. This one describes what the alternative economy does with the nutrients the mainstream declines to measure.

The core thesis

The supplement store is not simply the parasite of the medical mainstream’s failures. It is its functional counterpart. The mainstream produces the deficit by institutional negligence. The store monetizes the deficit by occupying the vacuum. The two stabilize each other. The mainstream needs a commercial escape route to exist so it is not held solely responsible for the symptoms it does not treat. The store needs the mainstream to refuse to recommend, because if the recommendation became universal the market would collapse into a prescription.

Both know. Both do nothing. That is what makes them counterparts.

What the store is guilty of

Monetizing what should be a right. It sells the physiological substrates the medical system has already declined to provide. What should be a right is bought. Those who cannot pay do not have access. The right becomes an income.

Living off the status quo. The store’s business depends on the mainstream continuing to refuse. Every guideline that says “insufficient evidence for supplementation” widens the store’s market. Every physician who declines to test for magnesium sends a customer through the door. The store is not an alternative to the failure; it is its economic beneficiary.

Neglecting what is not profitable. Basic riboflavin at a dollar a bottle is not the store’s product. The product is the newest, the branded, the “revolutionary”. Pauling spent his life saying the opposite: take large amounts of the vitamins that are inexpensive. The store does exactly the reverse. Small doses, proprietary formulations, marketing multipliers.

The permanent pursuit of the new. Every six months another compound announced as revolutionary at three digits per bottle. Nicotinamide riboside at forty to sixty dollars a month. NMN at fifty to eighty. Spermidine at thirty. Fisetin at twenty to forty. Urolithin A at fifty to seventy. Meanwhile riboflavin 400 mg for migraine has been in the Cochrane database for twenty years, at roughly five dollars a month, unchanged, uninteresting, unmarketed. The economic model requires novelty because the old no longer pays.

Proprietary formulations, artificially inflated prices. Chelated, liposomal, activated, patented, delivered, buffered. A percentage of these claims corresponds to a real bioavailability difference. A larger percentage is packaging language that justifies the multiplication of the price by three or ten. Biological ignorance in the buyer is the industry’s operating condition.

The confusion between two meanings of “natural”. Natural because the body needs it has been replaced by natural because it grows in a plant. The body knows only the molecule. Ascorbate crystals and ascorbate from rose hip extract are the same substance for the body’s biochemistry. The store sells the second at ten times the price of the first, and calls the first “synthetic” as if the body could tell the difference. Pauling himself spent years correcting this error inside the high-dose vitamin community.

Pauling’s quarrel with the community he helped create

Linus Pauling spent the last three decades of his life articulating a case for high-dose ascorbate, and for the therapeutic use of vitamins in general, that founded what came to be called orthomolecular medicine. He also spent them, less visibly, arguing with the supplement community that had grown around him. The two arguments were the same argument.

His central practical recommendation was that people should take large amounts of the vitamins that are inexpensive. Ascorbate crystals in bulk, niacin at pharmaceutical dose, high-dose B-complex, none of it proprietary, none of it branded, none of it “delivered”, none of it “activated”. His justification was chemical: the body knows the molecule, not the label; ascorbate is ascorbate whether it was crystallized from a fermentation vat or extracted from a rose hip; the price differential between the two carries no biological information.

By the 1980s, an increasingly organized supplement industry had done to Pauling’s message what the food industry had done to Pauling’s biology. It kept the words and inverted the practice. “Natural” was reinterpreted to mean derived from a plant, which allowed a mark-up factor of five to ten on the same molecule. Small doses were repackaged with proprietary language to justify prices Pauling had explicitly warned against. The newest, most patented, most story-laden product replaced the boring effective one. Pauling continued, into his last decade, to write letters correcting the confusion. The confusion won.

That trajectory is instructive on the specific point this piece names. The functional counterpart of a medical system that refuses to prescribe the right thing is not a market that provides the right thing. It is a market that provides an adjacent, more expensive, more storyable thing. The supplement community did not fail Pauling by accident. It failed him by the same economic logic that structured its emergence. The boring, cheap, unpatentable substrate does not sustain a business. Only its adjacent branded relative does.

What the store is not

I would never wish these stores to disappear. They are often the only route. In the absence of a rights architecture, the market is what remains. The alternative to a bad commercial provision is not, today, a good public provision. It is nothing.

That is why the store’s role is troubling. It is the only door open, and it charges rent at the threshold of the right.

Lack of social consciousness personified

They know, or they could know. They do not act. The information is not hidden from them; it is the material of their trade. And yet the store’s shelves are organized by the market’s logic, not by the physiology’s. What sells goes to eye level. What matters most and costs least goes to the bottom shelf, or is absent.

Are there exceptions? Few, and rarely at scale.

• Third-party verifiers (ConsumerLab, USP Verified, NSF): they do not sell, they certify. They play a real role but are marginal in visibility.
• Clinician brands (Thorne, Pure Encapsulations, Designs for Health): quality-focused, formulation-coherent, but expensive and gatekept behind practitioners.
• Public fortifications (folate in flour, iodine in salt): the structural exception. When the state acts, the rent extraction disappears. The physiological right is delivered at cost.
• Clinician-authors (Alan Gaby, Jonathan Wright, Michael Murray): a literature written outside the sales relationship, honest and useful.
• The Life Extension Foundation publishes and funds some research, but it also sells. The ambivalence is internal.

Beyond these, near-total commercial capture is the rule.

The dialectical point

If this text has a punchline, it is that the physiological-rights argument cannot be replaced by “buy better supplements”. The store is not the answer. The store is the shadow the answer’s absence casts. As long as the substrates people need are commercial products rather than rights, someone will sell them badly, and the failure to sell them well will be less scandalous than the failure to recognize them as rights.